What is Receptor Life Sciences?
Receptor Life Sciences is a pharmaceutical company focused on addressing central nervous system (CNS) disorders that currently have limited safe and effective treatment options. The company leverages FDA-approved drug-delivery technologies to create novel therapeutic solutions. This strategic approach aims to accelerate the development and potential market entry of its innovative treatments.
How much funding has Receptor Life Sciences raised?
Receptor Life Sciences has raised a total of $39.7M across 1 funding round:
Series A
$39.7M
Series A (2022): $39.7M with participation from Granite Point Capital
Key Investors in Receptor Life Sciences
Granite Point Capital
Granite Point Capital Management is a financial services firm specializing in capital management and investment strategies, likely focusing on institutional investors and high-net-worth individuals seeking tailored financial solutions.
What's next for Receptor Life Sciences?
The substantial enterprise-level funding indicates Receptor Life Sciences is poised for significant scaling and advancement of its therapeutic pipeline. This capital injection will likely fuel further research and development, clinical trials, and potential expansion of its operational capacity. The company's focus on CNS disorders, coupled with its use of established drug-delivery technologies, positions it for strategic growth and potential market disruption in a critical healthcare sector.
See full Receptor Life Sciences company page
